Mid-Tier Drugmakers and Drug Discovery Firms Q1 FY2027: Growth and profit leaders split

The three companies differ in both their sources of growth and how they generate profit. Ono and Nippon Shinyaku reported first-quarter results for FY2027. Peptide Dream reported its second quarter for FY2026, so direct comparisons require caution.

• Product growth is driving sales. Nippon Shinyaku benefited from Arleada and Fintepla, with expanding sales of key products supporting revenue growth.
• Sales and profit moved in opposite directions. Ono's revenue fell after its co-promotion of Farxiga tablets ended. Cost cuts and royalty income, however, lifted profit.
• Drug discovery investment has yet to pay off. Peptide Dream grew its radiopharmaceutical business, but that was not enough to cover drug development losses, leaving it in the red.
• Pricing and approvals matter. Drug price revisions affected Ono's sales. Product approvals and broader sales remain important for all three companies.

The companies are being separated by growing products and their ability to turn sales into earnings.

Nippon Shinyaku stood out for growth momentum. Revenue reached ¥49.1 billion, up 24.1% from a year earlier, outpacing Ono's ¥116.2 billion, down 8.9%. Operating profit rose 22.1% to ¥12.3 billion, delivering growth in both sales and profit.

Ono led in operating profit. Earnings rose 39.4% to ¥30.7 billion, well above Nippon Shinyaku's ¥12.3 billion, up 22.1%. Cost reductions and royalty income offset the impact of lower sales.

Peptide Dream faced the biggest challenges. Revenue increased 8.0% to ¥9.2 billion, but it recorded an operating loss of ¥2.5 billion. That contrasted with Nippon Shinyaku's profit, as radiopharmaceutical growth was not enough to absorb drug discovery costs.

Nippon Shinyaku led in revenue growth, while Ono was ahead in operating profit size and growth. The results divided growth stocks from profit leaders.

Ono is adjusting to a changing earnings structure after the end of a sales agreement. The loss of ¥25.1 billion in Farxiga tablet sales from the year-earlier period and drug price revisions weighed on revenue. Cost cuts and royalty income helped protect profit. The company left its full-year forecast unchanged.

Nippon Shinyaku is relying on expanding product sales for growth. Arleada generated ¥3.6 billion in sales and Fintepla ¥1.5 billion. The company maintained an operating margin of 25.1% while increasing research and development spending. It plans an annual dividend of ¥124.

Peptide Dream is building its radiopharmaceutical business. Revenue rose 8.0% from a year earlier, while its operating loss narrowed to ¥2.5 billion from ¥2.6 billion. For the full year, it forecasts revenue of ¥32 billion and operating profit of ¥4.6 billion. Turning the first-half loss into a full-year profit will depend on monetization in the second half.

All three companies kept their full-year forecasts unchanged. Peptide Dream differs from the other two because it expects to swing from a loss to a profit.

The impact varies by company, but pharmaceuticals and drug discovery share several sources of uncertainty.

• Drug price revisions can reduce sales and profit from existing medicines.
• Patent expirations and competing drugs can erode sales of key products.
• Clinical trial results and regulatory reviews can delay new drug commercialization.
• Research and sales expenses can come before revenue, preventing sales growth from translating into profit.
• Contract endings and overseas sales trends can affect results when companies rely on contract income or royalties.

For Nippon Shinyaku, key issues include the approval decision for deramiocel and patent litigation involving Viltepso. For Peptide Dream, investors will focus on contract revenue in the second half and progress toward a return to profit.

Ono ranked first in both revenue and operating profit, followed by Nippon Shinyaku and then Peptide Dream. Ono's operating margin of 26.4% also exceeded Nippon Shinyaku's 25.1%, a gap of 1.3 percentage points.

Growth rates tell a different story. Nippon Shinyaku led revenue growth, up 24.1%, while Ono led operating profit growth, up 39.4%. Peptide Dream increased sales but remained loss-making, making its ability to monetize its business key to changing its position.

The comparison covers only three companies, and their reporting periods are not aligned. The industry averages presented also cannot necessarily be taken as representative of the sector as a whole.

Those seeking to join a growth company may want to consider roles tied to expanding sales of new products, as at Nippon Shinyaku. Sales and marketing teams need to communicate product characteristics effectively to healthcare professionals.

At Ono, a key focus is reshaping the earnings structure after the end of a sales agreement. Cost management and coordination with partners are also important to the business. At Peptide Dream, employees can gain experience translating research results into business revenue, though the pace of its return to profitability is worth watching.

Research is not the only function that shapes results. Regulatory affairs, business development, manufacturing and sales also play important roles. Candidates should weigh a company's stage of growth against the work they want to do.